- Home
- ACIU vs AOMR Comparison
ACIU vs AOMR Comparison
Compare ACIU & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- AOMR
- Stock Information
- Founded
- ACIU 2003
- AOMR 2018
- Country
- ACIU Switzerland
- AOMR United States
- Employees
- ACIU N/A
- AOMR N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- AOMR Real Estate Investment Trusts
- Sector
- ACIU Health Care
- AOMR Real Estate
- Exchange
- ACIU Nasdaq
- AOMR Nasdaq
- Market Cap
- ACIU 247.4M
- AOMR 228.8M
- IPO Year
- ACIU 2016
- AOMR 2021
- Fundamental
- Price
- ACIU $1.98
- AOMR $9.56
- Analyst Decision
- ACIU Strong Buy
- AOMR Buy
- Analyst Count
- ACIU 2
- AOMR 5
- Target Price
- ACIU $12.00
- AOMR $11.90
- AVG Volume (30 Days)
- ACIU 197.4K
- AOMR 131.4K
- Earning Date
- ACIU 03-13-2025
- AOMR 03-04-2025
- Dividend Yield
- ACIU N/A
- AOMR 13.38%
- EPS Growth
- ACIU N/A
- AOMR N/A
- EPS
- ACIU N/A
- AOMR 1.17
- Revenue
- ACIU $30,136,397.00
- AOMR $51,458,000.00
- Revenue This Year
- ACIU $120.91
- AOMR N/A
- Revenue Next Year
- ACIU $13.82
- AOMR $3.50
- P/E Ratio
- ACIU N/A
- AOMR $8.18
- Revenue Growth
- ACIU 84.51
- AOMR N/A
- 52 Week Low
- ACIU $1.95
- AOMR $8.88
- 52 Week High
- ACIU $4.98
- AOMR $13.32
- Technical
- Relative Strength Index (RSI)
- ACIU 27.05
- AOMR 41.74
- Support Level
- ACIU $1.95
- AOMR $9.56
- Resistance Level
- ACIU $2.05
- AOMR $9.73
- Average True Range (ATR)
- ACIU 0.13
- AOMR 0.16
- MACD
- ACIU -0.02
- AOMR 0.01
- Stochastic Oscillator
- ACIU 6.38
- AOMR 26.51
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.